0001628280-20-004260.txt : 20200327 0001628280-20-004260.hdr.sgml : 20200327 20200327210341 ACCESSION NUMBER: 0001628280-20-004260 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200101 FILED AS OF DATE: 20200327 DATE AS OF CHANGE: 20200327 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: REICHLING STEVEN CENTRAL INDEX KEY: 0001556290 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-31822 FILM NUMBER: 20753641 MAIL ADDRESS: STREET 1: 7000 NORTH BROADWAY, BUILDING 3-307 CITY: DENVER STATE: CO ZIP: 80221 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Accelerate Diagnostics, Inc CENTRAL INDEX KEY: 0000727207 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 841072256 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3950 S. COUNTRY CLUB ROAD #470 STREET 2: BUILDING 3-307 CITY: TUCSON STATE: AZ ZIP: 85714 BUSINESS PHONE: 303-863-8088 MAIL ADDRESS: STREET 1: 3950 S. COUNTRY CLUB ROAD #470 STREET 2: BUILDING 3-307 CITY: TUCSON STATE: AZ ZIP: 85714 FORMER COMPANY: FORMER CONFORMED NAME: ACCELR8 TECHNOLOGY CORP DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: HYDRO SEEK INC DATE OF NAME CHANGE: 19880802 4 1 wf-form4_158535740296011.xml FORM 4 X0306 4 2020-01-01 0 0000727207 Accelerate Diagnostics, Inc AXDX 0001556290 REICHLING STEVEN C/O ACCELERATE DIAGNOSTICS, INC. 3950 S. COUNTRY CLUB ROAD, SUITE 470 TUCSON AZ 85714 0 1 0 0 Chief Financial Officer Employee Stock Option (right to buy) 16.9 2020-01-01 4 A 0 12634 3.96 A 2030-01-01 Common Stock 12634.0 12634 D This Form 4 was inadvertently not filed within the required time following the transaction date of January 1, 2020. Option awards vest in equal monthly amounts over twelve months, with the first installment vesting on January 31, 2020. The options were issued to the reporting person under the 2020 Salary Waiver and Nonqualified Stock Option Grant Plan (the "Sub-Plan") established pursuant to the Accelerate Diagnostics, Inc. 2012 Omnibus Equity Incentive Plan. Pursuant to the terms of the Sub-Plan, the reporting person irrevocably waived $50,000 of base compensation scheduled to be paid to the reporting person in 2020 in exchange for such options. /s/ Steve Reichling 2020-03-27